MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and...
6 insider purchases on record · latest filing 2026-07-28.
Insiders have also filed 138 sale transactions at MPLT.